Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
New peace laureate: Iran's arrest of Mohammadi 'confession of fear' - 2Pick Your Number one Sort Of Music
- 3What happened to Eleven after the ambiguous 'Stranger Things' series finale? Millie Bobby Brown knows — but 'swore herself to secrecy'
- 4The Forgotten BMW Coupe That Turned a 5 Series Into Something Far More Exotic
- 5Study reveals how fast weight returns after ending GLP-1 drugs
- Russia Establishing Long-Range Drone Bases In Belarus, Warns Ukraine
- Foreign military officials can become Israel's ambassadors, senior IDF commander tells 'Post'
- Experience Unrivaled Sound: Top Speakers You Really want to Hear
- Iranian-linked drone attack kills Kurdish couple in northern Iraq
- Palestinian infant freezes to death in Gaza as Israel keeps blocking aid
- Going with Children: Tips for Tranquil Family Get-aways
- 21 Things You Ought to Never Tell Your Childless Companion
- Nations for Rock Climbing
- Home Plan Tips for Seniors
